The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Patient perspectives on BCMA-targeted therapies for multiple myeloma: A survey conducted in a patient advocacy group.
 
Jennifer M. Ahlstrom
Consulting or Advisory Role - Bristol-Myers Squibb; Janssen; Pfizer; Sanofi; Takeda
 
Dee Lin
Employment - Janssen
Stock and Other Ownership Interests - Johnson & Johnson
 
Nathan W. Sweeney
Research Funding - Adaptive Biotechnologies (Inst); Janssen; Takeda (Inst)
 
Bingcao Wu
Employment - Janssen
Stock and Other Ownership Interests - Johnson & Johnson
 
Katharine Gries
Employment - Janssen Research & Development
Stock and Other Ownership Interests - Janssen (Inst)
 
Nina Kim
Employment - Janssen
Stock and Other Ownership Interests - Johnson & Johnson
 
Saurabh Patel
Employment - Janssen
Stock and Other Ownership Interests - Johnson & Johnson
 
Douglas W. Sborov
Consulting or Advisory Role - Abbvie; Bristol-Myers Squibb/Celgene; GlaxoSmithKline; Janssen; Legend Biotech; Pfizer; Sanofi; Skyline Diagnostics
 
Jesus G. Berdeja
Consulting or Advisory Role - Bluebird Bio (Inst); Bristol-Myers Squibb (Inst); Celgene (Inst); crispr therapeutics (Inst); Janssen (Inst); Kite, a Gilead company (Inst); Legend Biotech (Inst); Roche (Inst); Secura Bio (Inst); Takeda (Inst)
Research Funding - 2Seventy bio (Inst); Abbvie (Inst); Acetylon Pharmaceuticals (Inst); Amgen (Inst); Bluebird Bio (Inst); Bristol-Myers Squibb (Inst); C4 Therapeutics (Inst); CARsgen Therapeutics (Inst); Cartesian Therapeutics (Inst); Celgene (Inst); Celularity (Inst); crispr therapeutics (Inst); EMD Serono (Inst); Fate Therapeutics (Inst); Genentech/Roche (Inst); GlaxoSmithKline (Inst); Ichnos Sciences (Inst); Incyte (Inst); Janssen (Inst); Karyopharm Therapeutics (Inst); Lilly (Inst); Novartis (Inst); poseida therapeutics (Inst); Sanofi (Inst); Takeda (Inst); Teva (Inst)
 
Larry D. Anderson, Jr
Honoraria - Abbvie; Amgen; BeiGene; Bristol-Myers Squibb/Celgene; Cellectar; GlaxoSmithKline; janssen; Karyopharm Therapeutics; Oncopeptides; Prothena
Consulting or Advisory Role - Abbvie; amgen; BeiGene; Bristol-Myers Squibb/Celgene; Cellectar; GlaxoSmithKline; janssen; Karyopharm Therapeutics; Oncopeptides; Prothena
Research Funding - amgen; bms; celgene; GlaxoSmithKline; janssen; Karyopharm Therapeutics
 
Jinhai Huo
Employment - Bristol-Myers Squibb; Janssen
Stock and Other Ownership Interests - Johnson & Johnson/Janssen
 
Jay R Hydren
Research Funding - Adaptive Biotechnologies; GlaxoSmithKline; Janssen; Regeneron; Sanofi; Takeda